Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas

Abstract

ABSTRACT Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful tools to combat human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1-specific bNabs are capable of cross-neutralizing distantly related simian immunodeficiency viruses (SIVs) infecting central ( Pan troglodytes troglodytes ) (SIVcpz Ptt ) and eastern ( Pan troglodytes schweinfurthii ) (SIVcpz Pts ) chimpanzees ( n = 11) as well as western gorillas ( Gorilla gorilla gorilla ) (SIVgor) ( n = 1). We found that bNabs directed against the CD4 binding site ( n = 10), peptidoglycans at the base of variable loop 3 (V3) ( n = 5), and epitopes at the interface of surface (gp120) and membrane-bound (gp41) envelope glycoproteins ( n = 5) failed to neutralize SIVcpz and SIVgor strains. In addition, apex V2-directed bNabs ( n = 3) as well as llama-derived (heavy chain only) antibodies ( n = 6) recognizing both the CD4 binding site and gp41 epitopes were either completely inactive or neutralized only a fraction of SIVcpz Ptt strains. In contrast, one antibody targeting the membrane-proximal external region (MPER) of gp41 (10E8), functional CD4 and CCR5 receptor mimetics (eCD4-Ig, eCD4-Ig mim2 , CD4-218.3-E51, and CD4-218.3-E51-mim2), as well as mono- and bispecific anti-human CD4 (iMab and LM52) and CCR5 (PRO140, PRO140-10E8) receptor antibodies neutralized >90% of SIVcpz and SIVgor strains with low-nanomolar (0.13 to 8.4 nM) potency. Importantly, the latter antibodies blocked virus entry not only in TZM-bl cells but also in Cf2Th cells expressing chimpanzee CD4 and CCR5 and neutralized SIVcpz in chimpanzee CD4 + T cells, with 50% inhibitory concentrations (IC 50 s) ranging from 3.6 to 40.5 nM. These findings provide new insight into the protective capacity of anti-HIV-1 bNabs and identify candidates for further development to combat SIVcpz infection. IMPORTANCE SIVcpz is widespread in wild-living chimpanzees and can cause AIDS-like immunopathology and clinical disease. HIV-1 infection of humans can be controlled by antiretroviral therapy; however, treatment of wild-living African apes with current drug regimens is not feasible. Nonetheless, it may be possible to curb the spread of SIVcpz in select ape communities using vectored immunoprophylaxis and/or therapy. Here, we show that antibodies and antibody-like inhibitors developed to combat HIV-1 infection in humans are capable of neutralizing genetically diverse SIVcpz and SIVgor strains with considerable breadth and potency, including in primary chimpanzee CD4 + T cells. These reagents provide an important first step toward translating intervention strategies currently developed to treat and prevent AIDS in humans to SIV-infected apes.